The DESTINY PanTumor01 trial, which included patients with multiple solid tumor types based on NGS-detected HER2 mutations, reported an overall response rate of 29.4% but included only six patients with gynecologic cancers (Li et al., 2024). This evidence concerns the gene ERBB2 and female reproductive organ cancer.